Cellectis plans Phase 1 trial of .HEAL-101 in China, expects initial data in second half of 2027

• Cellectis announced preclinical results for .HEAL-101, its gene-editing candidate for severe hypertriglyceridemia.
• The findings will be presented October 29 at the European Society of Gene and Cell Therapy congress in Hamburg.
• A single dose substantially reduced triglycerides in a mouse disease model, with editing activity restricted to the liver.
• A Phase 1 investigator-initiated trial is planned in China, with preliminary clinical data expected in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006873), on October 28, 2026, and is solely responsible for the information contained therein.